All Stories

  1. Establishing a MoCA cut-off point for cognitive impairment detection in Mexican people living with Parkinson's disease: A comprehensive assessment (level II) approach
  2. Differences and contributors to global cognitive performance in the underrepresented Latinx Parkinson’s disease population
  3. Breaking the gender barrier: a study on enrollment trends in medical specialties at the Universidad Nacional Autónoma de México
  4. Association between alterations in sleep spindles and cognitive decline in persons with Parkinson’s disease
  5. Weak association between total alpha‐synuclein reflex tear levels and non‐motor symptoms burden in Parkinson's disease
  6. A Characterization of Central Auditory Processing in Parkinson’s Disease
  7. The Importance of Standardized Assessment
  8. Levodopa Versus Levodopa Sparing in Early Parkinson‘s Disease: Can we Meet Halfway?
  9. Electrocardiographic approach strategies in patients with Parkinson disease treated with deep brain stimulation
  10. Establishment of induced pluripotent stem cell lines derived from Parkinson’s disease Mexican patients: A sporadic (UNAMi002-A) and a familial (UNAMi003-A) case carrying a mutation in PINK1
  11. Impulse control disorders and its association to medication use and other associated factors in patients with Parkinson's disease
  12. Pro-inflammatory cytokines levels in tears and dry eye disease in Parkinson’s disease
  13. Investigación en enfermería: Una visión actual
  14. Determinants and impact of alexithymia on quality of life in Parkinson's disease
  15. Is there any correlation between alpha-synuclein levels in tears and retinal layer thickness in Parkinson's disease?
  16. Association between cardiometabolic comorbidities and Parkinson’s disease in a Mexican population
  17. Experience with Creutzfeldt-Jakob disease in a single referral center in Mexico. Case series
  18. Generation of a human induced pluripotent stem cell line (UNAMi001-A) from a Mexican patient with sporadic Parkinson’s disease
  19. Experiencia con la enfermedad de Creutzfeldt-Jakob de un único centro de referencia en México. Análisis de una serie de casos
  20. Fellowship training: a collateral damage of Covid-19 pandemic
  21. Naturalistic Study of Depression Associated with Parkinson’s Disease in a National Public Neurological Referral Center in Mexico
  22. Satisfaction With Telemedicine Consultation as Follow-Up Visit in Patients with Parkinsonism and Essential Tremor in during the Covid-19 Pandemic
  23. Assessment of therapeutic strategies for management of impulse control disorder in Parkinson’s disease
  24. Asociación entre comorbilidades cardiometabólicas y enfermedad de Parkinson en población mexicana
  25. Frontal functional connectivity and disease duration interactively predict cognitive decline in Parkinson's disease
  26. Incidencia y distribución geográfica de la enfermedad de Parkinson en México
  27. Malnutrition and Associated Motor and Non-motor Factors in People with Parkinson's Disease
  28. Lower Urinary Tract and Gastrointestinal Dysfunction Are Common in Early Parkinson’s Disease
  29. Neuropsychiatric profile of patients with craniocervical dystonia: A case-control study
  30. Independence of Coping Styles With the Patient–Doctor Relationship and Shared Decision-Making in People With Parkinson’s Disease
  31. Teaching neurology to “Millennials:” Basic concepts and recommendations
  32. Association Between Somatization and Nonmotor Symptoms Severity in People With Parkinson Disease
  33. Factores asociados con deterioro cognitivo en una cohorte mexicana multicéntrica de Parkinson: estudio transversal comparativo
  34. Falls in persons with Parkinson's disease: Do non-motor symptoms matter as much as motor symptoms?
  35. Incidence rates of Parkinson’s disease in Mexico: Analysis of 2014-2017 statistics
  36. Air Pollution, Multiple Sclerosis and its Relevance to Mexico City
  37. Terapias de infusión en la enfermedad de Parkinson avanzada
  38. Brief historical review of Parkinson’s disease at 200 years of its description
  39. Diseño y evaluación curricular de un curso de posgrado de alta especialidad en medicina
  40. Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center
  41. Breve recorrido histórico de la enfermedad de Parkinson a 200 años de su descripción
  42. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease
  43. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients
  44. Etiología, fenomenología, clasificación y tratamiento de la distonía
  45. Indirect Costs of Parkinson Disease Health Care in the National Institute of Neurology and Neurosurgery in the Mexico City
  46. Impulse control disorders in Parkinson's: Sleep disorders and nondopaminergic associations
  47. Brain oscillations reveal impaired novelty detection from early stages of Parkinson's disease
  48. Two-hundred Years Later: Is Parkinson�s Disease a Single Defined Entity?
  49. Premotor symptoms and the risk of Parkinson’s disease: A case-control study in Mexican population
  50. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative a...
  51. Association of polymorphisms and reduced expression levels of the NR4A2 gene with Parkinson's disease in a Mexican population
  52. Spotlight on olfactory dysfunction in Parkinson's disease
  53. Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms
  54. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
  55. Clinical Determinants of Parkinson's Disease-associated Pain Using the King's Parkinson's Disease Pain Scale
  56. Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson’s Disease: A Retrospective Study
  57. Frequency and clinical correlates of postural and striatal deformities in Parkinson’s disease
  58. A systematic review and mixed treatment comparison of monotherapy in early Parkinson’s disease: implications for Latin America
  59. Visuospatial, visuoconstructive and visuoperceptive functioning in patients with Parkinson's disease
  60. Theory of the mind in subjects with Parkinson's disease: A case-control study
  61. Lack of Association between Impulse Control Disorders and REM Sleep Behavior Disorder in Patients with Parkinson’s Disease
  62. Convergent validation of EQ-5D-5L in patients with Parkinson's disease
  63. Delusional Parasitosis as a Treatment Complication of Parkinson Disease
  64. No Difference on Adherence Between Immediate-Release Versus Extended-Release Dopamine Agonists in Uninsured Subjects with Parkinson's Disease
  65. Impact of Neuropsychiatric Symptoms on the Quality of Life of Subjects with Parkinson’s Disease
  66. Electroconvulsive therapy in Parkinson´s disease
  67. Factores asociados a la calidad de vida de sujetos con enfermedad de Parkinson y a la carga en el cuidador
  68. Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study
  69. Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson’s Disease
  70. Relación entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson
  71. A Polysomnographic Study of Parkinson’s Disease Sleep Architecture
  72. Impulse control and related disorders in Mexican Parkinson's disease patients
  73. Comparing the accuracy of different smell identification tests in Parkinson’s disease: Relevance of cultural aspects
  74. Simultaneous Presentation of Ocular Flutter in Two Sisters
  75. Clinical, imaging, and molecular findings in a sample of Mexican families with pantothenate kinase-associated neurodegeneration
  76. Comparison of the Montreal Cognitive Assessment and Mini Mental State Examination Performance in Patients with Parkinson’s disease with w Low Educational Background
  77. ¿Enfermedad de Parkinson o síndrome de enfermedad de Parkinson?
  78. Vas Eq-5d Utility Index In Parkinson’s Disease
  79. Direct Medical Costs Related To Parkinson’s Disease
  80. A reappraisal of the ten steps test for identifying atypical parkinsonism
  81. Low specificity and sensitivity of smell identification testing for the diagnosis of Parkinson?s disease
  82. Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA
  83. Cervical Dystonia
  84. Apathy and associated factors in Mexican patients with Parkinson’s disease
  85. Blood Pressure After Recent Stroke: Baseline Findings From the Secondary Prevention of Small Subcortical Strokes Trial
  86. Respuesta ortostática de la tensión arterial de pacientes con enfermedad de Parkinson inicial
  87. Clinical Determinants of Health-related Quality of Life in Mexican Patients with Parkinson’s Disease
  88. Prevalence and determinants of depression in Mexican patients with Parkinson's disease
  89. Overweight is more prevalent in patients with Parkinson's disease
  90. Opsoclonus Myoclonus Syndrome associated with GQ1b Antibodies
  91. Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson’s disease
  92. A prospective series of patients with hyperglycaemia-associated movement disorders
  93. Detección y manejo de síntomas no motores en la enfermedad de Parkinson: impacto en su prevalencia
  94. Relación entre el tipo y lado de inicio de la sintomatología motora con la frecuencia de síntomas no motores en la enfermedad de Parkinson
  95. Sympathetic Cooling in an Optically Trapped Mixture of Alkali and Spin-Singlet Atoms
  96. Relationship between the type and side of motor symptoms with the prevalence of non-motor symptoms in Parkinson's disease
  97. Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City
  98. Use of smell test identification in Parkinson's disease in Mexico: A matched case-control study
  99. SEQUENTIAL STAR FORMATION IN A COMETARY GLOBULE (BRC37) OF IC1396
  100. Uso clínico de autoanticuerpos en neurología
  101. Quality of life in patients with Parkinson's disease